{"doi":"10.1016/j.reval.2022.06.003","title":"The course of COVID-19 in patients with chronic spontaneous urticaria receiving omalizumab treatment","abstract":null,"journal":"Revue Française d'Allergologie","year":2022,"id":633332,"datarank":0.26876392038420827,"base_score":1.791759469228055,"endowment":1.791759469228055,"self_citation_contribution":0.26876392038420827,"citation_network_contribution":0.0,"self_endowment_contribution":0.26876392038420827,"citer_contribution":0.0,"corpus_percentile":null,"corpus_rank":null,"citation_count":5,"citer_count":0,"citers_with_citation_signal":0,"citers_with_endowment":0,"datacite_reuse_total":0,"is_dataset":false,"is_dataset_confidence":null,"is_data_producer":false,"deposit_databanks":null,"is_oa":false,"file_count":0,"downloads":0,"has_version_chain":false,"published_date":null,"fair_score":null,"fair_percentile":null,"algorithm_id":"datarank_citation_only_1hop_v6","ranking_scope":"data_only","authors":[{"id":1641948,"name":"G. Aytekin","orcid":null,"position":1,"is_corresponding":false},{"id":1641947,"name":"E. Atayik","orcid":null,"position":0,"is_corresponding":false}],"reference_count":0,"raw_metadata":{"has_enrichment":true,"resolved":true,"title":"The course of COVID-19 in patients with chronic spontaneous urticaria receiving omalizumab treatment","abstract":"<h4>Background and aim</h4>Although there are case reports and guideline recommendations that states omalizumab can be used in chronic spontaneous urticaria (CSU) patients during SARS-CoV-2 pandemic, there are scarce studies showing the course of Coronavirus disease 2019 (COVID-19) in CSU patients receiving omalizumab.<h4>Materials and methods</h4>A total of 370 patients with chronic urticaria were included in the study between June 2020 and December 31, 2020.<h4>Results</h4>Sixty patients (16.2%) became infected with the SARS-CoV-2. The rate of pneumonia and hospitalization were 4.1% and 1.9%. There was no significant difference was determined between the CSU patients with omalizumab treatment and the non-receivers in regard to the rate of SARS-CoV-2 (+) (<i>P</i>: 0.567) and in regard to the rate of SARS-CoV-2 related pneumonia and hospitalization (<i>P</i>: 0.331 and <i>P</i>: 0.690). Gender, duration of CSU, serum IgE levels, omalizumab treatment, and atopy were not found to be associated with an increased risk for SARS-CoV-2 positivity in patients with CSU.<h4>Conclusion</h4>Our study shows that the use of omalizumab does not increase the risk of COVID-19 infection, COVID-19-related pneumonia and COVID-19-related hospitalizations in CSU patients.","is_dataset_classified":null,"base_score":0.0,"endowment":0.0,"datacite_reuse_total":0,"file_count":0,"downloads":0,"views":0,"has_version_chain":false,"is_dataset":false,"is_oa":false,"pmid":"35721324","pmcid":"PMC9189112","openalex_id":null,"authors":[],"funders":[],"total_grants":0,"fwci":null,"citation_percentile":null,"influential_citations":0,"citation_trend":[],"oa_status":"hybrid","license":"cc-by-nc-nd","oa_locations":[{"url":"https://www.sciencedirect.com/science/article/pii/S1877032022003554/pdf","host_type":"publisher"},{"url":"https://api.elsevier.com/content/article/PII:S1877032022003554?httpAccept=text/xml","host_type":"publisher"},{"url":"https://api.elsevier.com/content/article/PII:S1877032022003554?httpAccept=text/plain","host_type":"publisher"},{"url":"https://www.ncbi.nlm.nih.gov/pmc/articles/9189112","host_type":"repository"},{"url":"https://doi.org/10.1016/j.reval.2022.06.003","host_type":"Unpaywall"},{"url":"https://europepmc.org/articles/PMC9189112","host_type":"Europe_PMC"},{"url":"https://europepmc.org/articles/PMC9189112?pdf=render","host_type":"Europe_PMC"}],"fields_of_study":[],"mesh_terms":[],"keywords":["Treatment","Omalizumab","Chronic Spontaneous Urticaria","Sars-cov-2"],"sdg_mappings":[],"linked_datasets":[],"clinical_trials":[],"software_tools":[],"database_accessions":[],"source":"live","citation_network_status":"fetched"},"created_at":"2026-08-06T11:52:13.205014Z","pmid":null,"pmcid":null,"fwci":null,"citation_percentile":null,"influential_citations":0,"oa_status":null,"license":null,"views":0,"total_file_size_bytes":0,"version_count":0,"fair_f":null,"fair_a":null,"fair_i":null,"fair_r":null,"fair_zscore":null,"fair_rationale":null,"fair_model":null,"fair_agent_version":null,"fair_fulltext_source":null,"fair_has_llm":null,"fair_computed_at":null,"clinical_trials":[],"software_tools":[],"db_accessions":[],"linked_datasets":[],"topics":[]}